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A B S T R A C T
End-stage renal disease patients have endothelial dysfunction and high plasma levels of ADMA
(asymmetric ω-NG,NG-dimethylarginine), an endogenous inhibitor of NOS (NO synthase). The
actual link between these abnormalities is controversial. Therefore, in the present study, we
investigated whether HD (haemodialysis) has an acute impact on NO-dependent vasodilation
and plasma ADMA in these patients. A total of 24 patients undergoing maintenance HD (HD
group) and 24 age- and gender-matched healthy controls (Control group) were enrolled. The
increase in forearm SkBF (skin blood flow) caused by local heating to 41 ◦C (SkBF41), known
to depend on endothelial NO production, was determined with laser Doppler imaging. SkBF41
was expressed as a percentage of the vasodilatory reserve obtained from the maximal SkBF
induced by local heating to 43 ◦C (independent of NO). In HD patients, SkBF41 was assessed on
two successive HD sessions, once immediately before and once immediately after HD. Plasma
ADMA was assayed simultaneously with MS/MS (tandem MS). In the Control group, SkBF41 was
determined twice, on two different days, and plasma ADMA was assayed once. In HD patients,
SkBF41 was identical before (82.2 +− 13.1%) and after (82.7 +− 12.4%) HD, but was lower than in
controls (day 1, 89.6 +− 6.1; day 2, 89.2 +− 6.9%; P< 0.01 compared with the HD group). In contrast,
plasma ADMA was higher before (0.98 +− 0.17 μmol/l) than after (0.58 +− 0.10 μmol/l; P< 0.01)
HD. ADMA levels after HD did not differ from those obtained in controls (0.56 +− 0.11 μmol/l).
These findings show that HD patients have impaired NO-dependent vasodilation in forearm skin,
an abnormality not acutely reversed by HD and not explained by ADMA accumulation.
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solid-phase extraction.
Correspondence: Dr Franc¸ois Feihl (email Francois.Feihl@chuv.ch).
C© The Authors Journal compilation C© 2009 Biochemical Society
www.clinsci.org
Cl
in
ic
al
 S
ci
en
ce
294 R. P. Engelberger and others
INTRODUCTION
Cardiovascular complications are the most important
cause of mortality in ESRD (end-stage renal disease)
patients [1]. In this population, one contributing factor to
increased cardiovascular risk might be the accumulation
of endogenous NOS (NO synthase) inhibitors such as
ADMA (asymmetric ω-NG,NG-dimethylarginine) [2,3].
This accumulation appears to be due in large part to a
down-regulated expression of DDAH (dimethylarginine
dimethylaminohydrolase), the enzyme which degrades
ADMA [4]. In CKD (chronic kidney disease) patients,
plasma ADMA levels are a strong independent predictor
of kidney disease progression [5,6] and of all-cause
cardiovascular mortality [7]. Furthermore, Matsumoto
et al. [8] have demonstrated in a rat model of CRF
(chronic renal failure) that ADMA is involved in
peritubular capillary loss, tubulointerstitial fibrosis and
proteinuria, thereby contributing to the progression of
CKD.
ADMA accumulation can be a direct cause of
endothelial dysfunction [9], which plays a pivotal role
in the development of atherosclerosis [10]. Endothelial
dysfunction, manifested by reduced endothelium-
dependent vasodilation, exists even with a mild chronic
impairment of renal function [11,12], and in uraemia, as in
many other pathologies, it has been attributed to reduced
bioavailability of endothelium-produced NO [13,14].
Elevated circulating levels of ADMA have been linked
to endothelial dysfunction in hypercholesterolaemia [15]
and in CKD patients [3,4]. The influence of a single HD
(haemodialysis) session on plasmaADMA levels has been
described in the literature as highly variable, with a mean
decrease after HD ranging from 0 to 84% [16]. The
impact of an HD-induced acute fall in plasma ADMA on
endothelial NO-dependent vasodilation is not known.
The aim of the present study was to test in ESRD
patients the hypothesis that an acute decrease in
ADMA levels in plasma after a single HD session
may improve endothelial dysfunction in the cutaneous
microcirculation.
Part of this work was presented at the XLV ERA-
EDTA meeting, Stockholm, Sweden, 10–13 May 2008,
and published in abstract form [16a].
MATERIALS AND METHODS
Subjects
A total of 24 patients on maintenance HD for more than
1monthwere enrolled (HDgroup; Table 1). Patientswith
arteriovenous fistulas on both forearms, dermatological
pathologies or treatment with organic nitrates were
excluded. All HD patients were anuric except for six
of them. The HD technical prescription during the HD
investigational sessions is described in Table 2 (Table 2).
Table 1 Demographic and clinical characteristics of the HD
patients
Values are means+− S.D. ACEI, angiotensin-converting enzyme inhibitor; ARB,
angiotensin II type 1 receptor.
Characteristic HD group (n = 24)
Age (years) 67.9+− 13.6
Gender (male/female) (n) 18/6
BMI (kg/m2) 25.6+− 4.5
Months on HD 41.6+− 68.4
Underlying renal disease (n)
Diabetic nephropathy 9
Hypertensive nephrangiosclerosis 17
Chronic glomerulonephritis 2
Cyclosporine induced nephropathy 2
IgA nephropathy 1
Other/unknown 6
Co-morbidities (n)
Diabetes 9
Coronary heart disease 8
Hypercholesterolaemia 12
Polyneuropathy 7
Smokers 8
Medication (n)
β-Adrenergic blockers 8
Calcium-channel blockers 8
ACEIs 7
ARBs 11
Antiplatelet therapy 11
Diuretics 8
Statins 13
Recombinant erythropoietin 19
The dialysate temperature was maintained constant at
37 ◦C. All patients had high-flux filters.
A total of 24 healthy subjects whowere matched to the
HD group for age and gender were recruited [Control
group; age, 68.8+− 11.7 years; 17 male and seven female;
BMI (body mass index), 24.7+− 2.3 kg/m2]. The control
subjects were all non-smokers, did not have cardiovascu-
lar or kidney disease, diabetes or dermatological disease,
and were not taking any medication.
All participants in the present study were Caucasians,
as skin colour influences laser Doppler flowmetry.
The studywas approved by the ethics committee of the
University of Lausanne and conformed to the principles
outlined in the Declaration of Helsinki. All participants
gave written informed consent.
Assessment of skin endothelial function
The measurement of microvascular SkBF (skin blood
flow) with laser Doppler flowmetry can be used for the
non-invasive assessment of endothelial function in
the human cutaneousmicrocirculation [17]. Local heating
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Table 2 Technical HD prescription
Values are means+− S.D. spKt/V urea , single pool Kt/V urea , according to the
second-generation Daugirdas formula [67]. Haemodiafiltration was always online.
Prescription
Duration of HD (min) 214.8+− 23.3
Filter type
Polysulfone 13 out of 24 patients
Polyamide 11 out of 24 patients
HD 19 out of 24 patients
Haemodiafiltration 5 out of 24 patients
Substitution volume (ml/min) 89.0+− 5.7
Blood flow rate (ml/min) 436.3+− 59.8
Dialysate flow rate (ml/min) 490.4+− 26.9
Ultrafiltration volume (kg) 2.5+− 0.8
spKt/V urea 1.4+− 0.2
of the skin to temperatures below 42 ◦C typically induces
a biphasic increase in SkBF with an initial peak and a
secondary sustained plateau after 20–30 min (thermal
hyperaemia). This plateau response is known to be
primarily mediated by the local generation of NO [18],
with recent findings supporting the production by eNOS
(endothelial NOS), rather than nNOS (neuronal NOS)
[19]. Thermal hyperaemia has been used in clinical studies
to investigate endothelium-dependent NO release [20].
Its decrease has been shown to be of prognostic value for
cardiovascular mortality in ESRD patients [21].
Measurement of SkBF
Laser Doppler flowmetry was carried out with a laser
Doppler imager (LDI; Moor Instruments), as described
previously [22,23]. This device allows the measurement
of dermal microvascular blood flow in a region of interest
with no skin contact. According to the principles of laser
Doppler flowmetry, SkBF is expressed in PUs (perfusion
units).
Local thermal hyperaemia
The change in SkBF induced by local warming of the skin
was recorded by means of temperature-controlled water-
filled chambers as described previously [23,24]. Local
temperature was set at 34 ◦C until SkBF was stable, then
was raised to 41 ◦C in 60 s and maintained at this level for
28 min. Subsequently, the temperature was increased to
43 ◦C for another 15 min to induce SkBFmax (maximum
SkBF) [25].
Analytical methods
Plasma levels of ADMA
ADMA determination in plasma was performed by elec-
trospray MS/MS (tandem MS). To 60 μl of plasma, 30 μl
of d7-ADMA ([2,3,3,4,4,5,5-2H7]-ADMA) at 1 μmol/l
(Cambridge Isotope Laboratories), 106 μl of water and
4 μl of formic acidwere added. The analyteswere purified
by μ-SPE (micro-solid-phase extraction) using the Oasis
MCX μElution Plate (Waters). The procedure comprised
of what is typical for SPE: conditioning of the μ-SPE
wells by methanol, application of the diluted samples,
wash steps with 2% (v/v) formic acid and methanol, and
finally elution with 1.25% (v/v) NH4OH in water.
Chromatographic analysis was performed using a
Rheos CPS-LC (Flux Instruments) and a PAL SYSTEM
autosampler (CTC Analysis). Separation of the analytes
was achieved at 30 ◦C using an Atlantis HILIC silica
2.1× 50 mm column (Waters). The mobile phases used
for the chromatographic separation were composed of
20 mmol/l ammonium formate, 0.4% (v/v) formic acid
in water and acetonitrile. The column effluent was mon-
itored using a TripleQuadrupole TSQQuantumDiscov-
ery (Thermo Scientific). The instrument was equipped
with an electrospray interface and was controlled by the
Xcalibur software (Thermo Scientific). The samples were
analysed in the positive-ionization mode operating in a
cone voltage of 4 kV. The tandem mass spectrometer was
programmed using the SRM (selected reaction monitor-
ing) mode to allow the [MH+] ions of ADMA atm/z 203
and that of the internal standard d7-ADMA at m/z 210
to pass through the first quadrupole (Q1) and into the
collision cell (Q2). The daughter ions for ADMA and d7-
ADMA are ofm/z 46. Calibration curves were computed
using the ratio of the peak area of the analytes and
internal standard using a weighted (1/x2) least-squares
linear regression analysis.
We did not assay the symmetric form of dimethy-
l-arginine [SDMA (symmetric ω-NG,N′G-dimethyl-
arginine)], which is devoid of inhibitory effect on NOS
activity [3].
Plasma levels of L-arginine
For practical reasons, l-arginine levels in plasma were
measured using a protocol in our laboratory based on
HPLC. The analysis was performed using an Agilent
1100 HPLC system. A reverse-phase was used for
chromatographic separation [Zorbax Eclipse C18 column
AAA (4.6× 150 mm; 3.5 μmol/l); Agilent Technologies].
Detection was done by fluorescence measurements at
340 nm (excitation) and 450 nm (emission). ChemStation
Rev B 03-01 software (Agilent Technologies) was used
for data acquisition and analysis.
An internal standard (50 μl of 1250 μmol/l δ-gluco-
saminic acid in 160 g/l 5-sulfosalicylic acid) was added
to 200 μl of plasma. The samples were mixed thoroughly
and incubated on ice for 1 h. The tubeswere centrifuged at
20800 g. Then, 30 μl of 200 mmol/l Na2HPO4 (pH 7.8)
was added to 120 μl of supernatant. The samples were
transferred into HPLC vials for injections.
Automatic pre-column derivatization with OPA-
3MPA was performed at room temperature (21–24 ◦C)
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using an autosampler program in accordance with the
manufacturer’s instructions (Agilent Technologies).
The mobile phase A was 40 mmol/l NaH2PO4 (pH 7.8),
and mobile phase B was acetonitrile/methanol/water
(9:9:2, by vol.). The separation was obtained at a flow
rate of 1 ml/min with a gradient program that allowed
for 2 min of 0% B, followed by a 26 min step that raised
mobile phase B to 20%. Then, washing at 100% B for
10 min and the equilibration steps at 0% B for 10 min
were performed for a total run of 48 min.
Experimental protocol
HD group
Each subject was examined on two separate visits 2 or
3 days apart. Caffeine-containing beverages were avoided
on the day of the experiments, and smokers were not
allowed to smoke for at least 8 h before examination.
The visits were on two successive HD sessions. Thermal
hyperaemia was recorded, and blood was drawn for
the determination of plasmaADMAand l-arginine at the
same visit, once in the hour before and once immediately
after HD, in a randomized order. The blood sample after
the HD session was collected after a short equilibration
period, as usually determined in order to measure
Kt/Vurea [dialysis quality; where K is dialyser clearance
for urea, t is time, andVurea is the urea distribution volume
(i.e. total bodywater)] in a standardized fashion. This was
as follows: dialysate flow stopped, ultrafiltration stopped,
blood flow reduced to 100 ml/min for 3 min, and blood
taken from the arterial line. Twelve patients attending the
morning HD session were thus examined in the morning
period, and the 12 patients attending the afternoon HD
session were assessed in the afternoon. Investigations
were not performed before and after the same HD
session for the following reasons: (i) we wanted to record
thermal hyperaemia on exactly the same skin site on both
occasions in order to avoid potential confounding by
spatial variation of the vasodilatory response [22], and
(ii) we have recently published results indicating that
thermal hyperaemia recorded on a particular site can be
diminished by previous heating of this site carried out a
few hours before [24]. Measurements were performed in
the forearm contralateral to the arteriovenous vascular
access. After an acclimatization period of 10 min, the
subjects were examined in the supine position with
the forearm under investigation supported by a vacuum
splint. The exact location of the site on the examined
forearm was marked on a transparent acetate film,
together with the anatomical outline of the forearm,
in order to exactly locate the same site for the SkBF
measurements performed during the second visit [22].
BP (blood pressure) and heart rate were measured
before and after the recording of thermal hyperaemia
on the contralateral arm using an automated electronic
device (Datascope Accutorr 1A; MS Cardio-Medical).
Skin temperature was also systematically measured using
a cutaneous probe (G. Me´traux). The investigations
were carried out in a quiet room with air conditioning.
Ambient temperature was systematically measured and
ranged from 23–26 ◦C.
Control group
Each participant in this group also had two separate
measurement sessions at the same timeof day as in theHD
group (sessions ‘before’ and ‘after’), also on two different
days. The experimental protocol was identical with that
followed in the HD group, except for the absence of HD
and for the fact that plasma ADMAwas determined only
once.
Data analysis
Values are presented as means+− S.D., or medians (range)
in the case of asymmetrical distributions. To take into
account the biphasic SkBF response to local heating
[18,23], local thermal hyperaemia was summarized as:
(i) baseline (average SkBF of the first twomeasurements);
(ii) initial peak (maximal SkBF in the first 6 min after the
beginning of heating); (iii) nadir (minimal SkBF after
the initial peak); (iv) plateau (average SkBF of the last
5 min at 41 ◦C); and (v) SkBFmax (average SkBF of the
last 5 min at 43 ◦C). SkBFmax is expressed in PUs, whereas
all of the other SkBF measurements are expressed as a
percentage of SkBFmax for normalization purposes [17].
Contrary to plateau SkBF, SkBFmax is independent of
endothelial NO, as are the initial peak and the nadir
[18,19].
Statistical analysis of the SkBF data was carried out
with univariate repeated-measures ANOVA.When the F
value was significant, pairwise comparisons were carried
out with modified Student’s t tests (i.e. Fisher-protected
least-significant difference). The α level of all tests was
set at 0.05. All computations were performed with JMP
software version 5.0.2 (SAS Institute).
RESULTS
Vital parameters and skin temperature values are sum-
marized in Table 3. SBP and DBP (systolic and diastolic
BPs respectively)were significantlyhigher inHDpatients
than in control subjects (P< 0.01). Compared with
the Control group, mean BP in the HD group was
significantly higher before (P< 0.01), but similar after,
the HD session. HD did not affect heart rate, which
was significantly higher in HD patients than in controls
(P< 0.01). Skin temperature at the forearm level was
slightly lower in HD patients than in controls (P< 0.05)
and was not influenced by HD. This difference may be
explained, at least in part, by a somewhat lower ambient
temperature in the examination room used with the HD
patients, which for practical reasons was located within
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Table 3 Vital parameters and response of SkBF to local heating (41 ◦C)
Values are means+− S.D. ∗∗P < 0.01 compared with after HD. ◦P < 0.05 and ◦◦P < 0.01 compared with the Control group.
HD group Control group
Parameter Before HD After HD ‘Before’ ‘After’
Vital parameter
SBP (mmHg) 146+− 23∗∗◦◦ 125+− 20 124+− 20 125+− 18
DBP (mmHg) 76+− 11∗∗◦◦ 66+− 14◦ 70+− 14 71+− 11
Mean BP (mmHg) 99+− 13∗∗◦◦ 86+− 13 88+− 13 89+− 14
Heart rate (beats/min) 75+− 13◦◦ 74+− 12◦◦ 63+− 8 61+− 7
Weight (kg) 75.8+− 17∗∗◦◦ 73.6+− 16.4 73.2+− 10.8 73.2+− 10.8
Skin temperature ( ◦C) 32.5+− 0.8◦ 32.6+− 1.0◦ 33.2+− 1.1 33.3+− 1.1
Ambient temperature ( ◦C) 24.2+− 0.4◦ 24.6+− 0.6◦ 24.8+− 0.7 25.0+− 0.8
SkBP response
Baseline (% of SkBFmax) 16.1+− 4.9 16.7+− 6.1 14.4+− 5.5 14.7+− 6.0
Initial peak (% of SkBFmax) 73.4+− 13.3 72.4+− 20.4 74.2+− 8.6 78.6+− 10.6
Nadir (% of SkBFmax) 51.5+− 15.5 50.5+− 17.9 59.0+− 9.9 59.0+− 14.2
Plateau (% of SkBFmax) 82.2+− 13.1◦◦ 82.7+− 12.4◦◦ 89.6+− 6.1 89.2+− 6.9
SkBFmax (PUs) 491+− 163◦◦ 475+− 174◦◦ 632+− 92 635+− 129
Figure 1 Response of SkBF to local heating in patients on chronic HD for ESRD and in control subjects
(A) SkBF is expressed in PUs; (B) SkBF is expressed as a percentage of the maximum SkBF at 43 ◦C. Patients on HD and control subjects were matched for age and
gender. Before HD, the hour that preceded one HD session; after HD, the hour that followed another HD session; ‘before’ and ‘after’, two measurements made 2 or 3 days
apart in the same control subject at the same time of day as in the patients. The two HD sessions (or in controls the two measurement sessions) were 2 or
3 days apart. Values are means+− S.D. of 24 subjects per group.
the HD ward, whereas the control subjects were studied
in the physiology laboratory.
As shown in Figure 1 and Table 3, SkBFmax [i.e. elicited
by heating at 43 ◦C (NO-independent) and expressed in
PUs] was significantly lower in the HD group than in the
Control group, and completely unaffected byHD.When
expressed as a percentage of SkBFmax, the plateau SkBF
[i.e. after 30 min of heating at 41 ◦C (NO-dependent)]
was significantly lower in HD patients than in controls,
whereas the initial peak and the nadir responses (both
independent of endothelial NO production [18,19]) did
not differ between the groups. None of the variables
derived from thermal hyperaemia was affected by HD.
In the Control group, the first and second thermal
hyperaemia were identical in every respect.
Measurements in themorning did not differ from those
in the afternoon in both HD patients and the Control
group (results not shown). There was no correlation
between the temperature of unheated skin (measured in
the vicinity of the thermally probed area) and any of the
parameters derived from thermal hyperaemia. This lackof
correlation makes it very unlikely that the slightly lower
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Figure 2 Effects of HD on plasma levels of ADMA and
L-arginine
In patients on HD, plasma ADMA and L-arginine levels were assessed in the hour
that preceded one HD session (before HD) and immediately after another HD
session (after HD). Plasma ADMA was obtained only once in the Control group.
(A) Boxes indicate the 25th, 50th and 75th percentile, and whiskers indicate the
5th and 95th percentile. (B) Individual changes before and after HD. ∗∗P < 0.01
and ∗∗∗P < 0.001 compared with the Control group; ◦◦◦P < 0.001 compared
with ‘before HD’.
unheated skin temperature of the patients could account
for the differences between the groups shown in Figure 1
and Table 3.
Blood was drawn for the determination of plasma
ADMA and l-arginine levels simultaneously with SkBF
measurements on both sessions in the HD group, and
on only one session in the Control group (Figure 2).
In the HD group, ADMA and l-arginine levels were
higher before HD (0.98+− 0.17 and 70+− 24 μmol/l
respectively) than after HD (0.58+− 0.10 and 49+−
19 μmol/l respectively; P< 0.001 for ADMA and
P= 0.005 for l-arginine). BeforeHD,ADMA levels were
also significantly higher and l-arginine levels significantly
lower than in the Control group (0.56+− 0.11 and 88+−
23 μmol/l; P< 0.001 for both analytes). After HD,
ADMAlevels of the patients did not differ from the values
of control subjects, whereas l-arginine was considerably
lower (49+− 19 μmol/l; P< 0.001). The median relative
decreases in plasmaADMA and l-arginine levels induced
by HD were −40 and −29% respectively, of the pre-
dialysis value, with a substantial variability between
patients (range for ADMA, −20 to −52%; range for
l-arginine, −66 to +117%) (Figure 2B).
The plasma concentration l-arginine/ADMA ratio has
been advocated as surrogate for NO production capacity
[15]. In patients, this ratio was considerably lower than in
Figure 3 Correlation between changes in plasma levels of
ADMA induced by HD and the corresponding changes in the
plateau SkBF response to local heating (41 ◦C)
Changes in SkBF are expressed as a percentage of SkBFmax elicited by subsequent
heating to 43 ◦C (see Figure 1).
control subjects [before HD, 66 (38–136) compared with
150 (112–242) in the Control group; P< 0.001] and there
was a small, but non-significant, increase in this ratio after
HD [80 (38–222); P= 0.06] (Figure 2).
There was no correlation between the changes
observed between the two HD sessions in the NO-
dependent SkBF plateau and the corresponding changes
in plasma ADMA (r2 = 0.05, P= 0.33; Figure 3), plasma
l-arginine (r2 = 0.00, P= 0.95) and l-arginine/ADMA
ratio (r2 = 0.02, P= 0.56).
DISCUSSION
In the present study, we have found that HD markedly
and transiently decreased the plasma levels of both
l-arginine and ADMA, with only a small non-significant
increase in the l-arginine/ADMA ratio. Concomitantly,
there was no acute influence ofHDon anNO-dependent
vasodilatory response in the skin microcirculation. These
results raise the possibility that, in ESRD patients,
removal of endogenous NOS inhibitors by HD is
not efficient in improving endothelial function due to
the concomitant changes induced in the availability of
l-arginine. Alternatively, mechanisms other than or in
addition to inhibition of eNOS by accumulated ADMA
may be responsible for endothelial dysfunction in ESRD.
Plasma L-arginine and ADMA levels
Pre-dialysis values
In the HD group before dialysis, plasma l-arginine was
30% lower and plasma ADMA was 40% higher in
comparison with values from the Control group, which
was matched for age and gender. Although not reported
constantly [26–28], an abnormally low level of circulating
l-arginine has been a frequent finding in previous studies
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of ESRD patients [29–33], possibly related to deficient
nutritional status [31], diminished l-arginine synthesis by
the kidney, chronic loss of this amino acid in the dialysate
[34], or stimulated transport into cells via the y+ cationic
amino-acid transporter [33].
Retention of ADMA has been uniformly found in
ESRD patients, although the relative increase in the
plasma level of this arginine analogue has varied between
studies from 1.3 to 10 times the normal value (reviewed in
[16]). Our pre-dialysis and control ADMA results are
in agreement with those obtained either with HPLC by
Fleck et al. [29], Wahbi et al. [35] and Schiel et al. [36]
or with LC-MS (as in the present study) by Martens-
Lobenhoffer et al. [37].
Acute impact of HD
In ESRD patients, the short-term effect of a single
HD session on the plasma levels of l-arginine has
been extremely variable between studies, with some
finding no change [27,28,32,38] while others reported
decreases ranging from 10–70% of pre-dialysis values
[26,39–41]. The present study clearly belongs to the
second category (Figure 2), although the results differed
considerably between patients, possibly because of a
variable redistribution of l-arginine between intracellular
and extracellular pools (keeping in mind that the former
is by far the larger) [42].
A recent systematic review identified 19 clinical studies
where the acute impact of HD on ADMA plasma
levels was documented in ESRD patients [16]. Findings
were highly variable between studies, with a mean
percentage reduction ranging from 0 to 84%. [16]. In
the present study, HD appeared efficient at decreasing
ADMAplasma levels (amean decrease of 40%), although
there was substantial variability between patients in that
respect. Low ADMA clearance during HD compared
with other substances of similar chemical structure might
be explained by significant protein binding [43]. The
influence of oxidative stress, pro-inflammatory cytokines
and pH changes on catabolism of ADMA as well as on
its uptake and release by erythrocytes [44] or other cells
[45] may also be involved.
Thermal hyperaemia as a non-invasive
means to evaluate NO-dependent
vasodilation in CKD
Two clinical studies have found that microvascular
endothelial function, as assessed with local thermal
hyperaemia, was depressed in ESRD patients [21,46],
and the present study confirms these results (Table 3).
Furthermore, a prospective study of CRF patients
showed that impaired skin thermal hyperaemia was
predictive of cardiovascular mortality after 2 years,
independently of other conventional risk factors [21].
Collectively, these findings support the validity of a
diminished plateau of thermal hyperaemia as an indicator
of endothelial dysfunction in the setting of CKD.
In our present study, the interpretation of differences
in plateau SkBF at 41 ◦C between patients and controls
is complicated by the unequal vasodilatory reserve of the
skin microcirculation in the two groups, as shown by
the markedly different SkBFmax (Figure 1 and Table 3).
In contrast with the submaximal SkBF plateau, SkBFmax
is insensitive to NOS inhibitors [18] and is thought
to depend directly on the local density of microvessels
(i.e. the vasodilatory reserve) [47]. In view of the
well-established association between hypertension and
rarefaction of skin capillaries [48] and considering the
markedly higher BP in the HD group compared with
the Control group (Table 3), it appears likely that the
lower SkBFmax measured in patients on HD was due,
at least in part, to the hypertension-related reduction
in skin capillary density. Another possible explanation
relates to the well-known angiogenic effect of NO [49].
In the mouse, chronic administration of a NOS inhibitor
induced capillary rarefaction, at least in the kidney
medulla [50]. Thus microvascular rarefaction in the HD
group might also have been promoted by chronic NO
deficiency, which is characteristic of CKD and can be
due, in part, to ADMA accumulation [34].
In view of these considerations, information on
functional (as opposed to structural) mechanisms which
potentially participate in the observed difference in
thermal hyperaemia between the two study groups
can only be extracted by comparing the vasodilatory
responses normalized to SkBFmax, as we have done in
the present study. The normalized NO-dependent [18]
plateau SkBF at 41 ◦C was lower in the HD group,
but the normalized NO-independent [18] early peak
was not (Table 3). These observations support a specific
impairment of NO-mediated vasodilation in the skin
microcirculation of renal failure patients.
Impact of HD on thermal hyperaemia
The HD prescription included the withdrawal of
an amount of fluid sufficient to cause significant
hypovolaemia (i.e. a mean ultrafiltration volume of
2.5 litres; Table 2), thus explaining the fall in BP that
occurred in the course of the session (Table 3). This in
turn may have triggered a baroreflex that could have had
an impact upon skin vasoreactivity.
Interestingly, despite an important BP decrease during
HD, basal SkBF as well as SkBFmax were not affected
(Table 3). This suggests stable haemodynamic conditions
in the cutaneous microcirculation even with important
systemic haemodynamic modifications, making this
method an interesting tool for the assessment of
microvascular function in various conditions.
The actual impact of HD on endothelial function
remains controversial. We did not find any difference in
the thermal hyperaemic response before and after HD.
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Therefore, at least in the dermal microcirculation, HD
does not appear to negatively or positively influence
NO-dependent vasodilation in the short term, although
its long-term impact in that respect cannot be inferred
from our present findings. Our present results are
consistent with some, but not all, previous findings
made in patients on maintenance HD. The HD session
had no effect on FMD (flow-mediated vasodilation) of
the brachial artery [51], endothelium-dependent vascular
reactivity assessed by applanation tonometry [28] or the
response of the skin microcirculation to iontophoretic
application of acetylcholine [52], an endothelium-
dependent vasodilator. However, some investigators have
found that endothelium-dependent vasodilation was
acutely reduced after HD, possibly because of the
induced oxidative stress [53,54], the amount of which
appears to depend on the type of dialysis filter used
[55]. Improvement in endothelial function immediately
after the HD session has also been reported [26,56,57];
however, we emphasize that, with one exception [52], all
of these studies did not specifically assess endothelium-
dependent vasodilation in the microcirculation.
ADMA and NO-dependent vasodilation
in CKD
In the present study, we observed no correlation between
plasma ADMA levels and endothelial NO-dependent
vasodilation in the cutaneousmicrocirculation (Figure 3).
More importantly, HD acutely reduced the plasma
concentration of ADMA (Figure 2), but did not have
any impact on NO-dependent vasodilation (Figure 1).
Our results are consistent with the findings of Chan
et al. [58], who observed a complete dissociation between
the changes in FMD and the changes in plasma ADMA
levels which followed an increase in the dose of dialysis
(i.e. a switch from conventional to nocturnal HD).
Another study in patients on peritoneal dialysis reported
that ADMA levels were related to basal, but not to
acetylcholine-stimulated, NO bioactivity in the forearm
circulation [59]. Cross et al. [56] did not find any
correlation before and after an HD session between
plasma ADMA or homocysteine concentrations and
FMD and they concluded that the impaired conduit
artery endothelial function in ESRD was due to the
total burden of circulation inhibitors rather any single
molecular species. On the other hand, Yilmaz et al. [60]
found a significant negative correlation between FMD
and ADMA levels before and 4 weeks after kidney trans-
plantation, suggesting that increased ADMA levels might
be one of the contributors to endothelial dysfunction in
ESRD patients. However, their study population was
much younger (mean age, 27.9+− 9.1 years) than those
in the studies by Chan et al. [58] (41+− 2 years), Cross
et al. [56] (43+− 3.5 years) and ours (the present study;
68+− 14 years), and the dialysis time of these patients
before transplantation was not reported. In CRF, it is
conceivable that the contribution of ADMA accumula-
tion to impaired NO-dependent vasodilation varies with
patient age and/or disease duration in this setting.
The dissociation between changes in ADMA levels
and changes in NO-dependent vasodilation observed
in two studies as well as in our present study could
be due to a concomitant reduction in NOS substrate
availability, as possibly reflected by the acute decrease
in plasma levels of l-arginine caused by HD (Figure 2).
However, this is not supported by the findings of Cross
et al. [56], who examined ESRD patients immediately
before anHD session andwere unable in these conditions
to augment the NO-dependent vasodilation of the
brachial artery (FMD) or of the forearmmicrovasculature
(intra-arterial infusion of acetylcholine) by the systemic
or intra-arterial infusion of l-arginine [61]. Another
explanation might reside in the capacity of endothelial
cells to concentrate ADMA. Cellular studies on bovine
aortic endothelial cells have shown that intracellular
ADMA levels could be 5–10 times higher than outside
the cell [45]. There is a continuous low-level production
of ADMA from the proteolysis of methylated arginine
residues on various proteins [3], but its concentration
is kept below a threshold concentration for inhibition
of NOS by the activity of DDAH, the enzyme
which degrades ADMA [4]. However under specific
conditions, such as the addition of ADMA to the
medium of cultured endothelial cells [45], administration
of exogenous ADMA to experimental animals or humans
[62] and DDAH deficiency in mice [9], intracellular
ADMA may reach levels sufficient to inhibit NOS
function and endothelium-dependent vasodilation. To
date, it is not known how the intracellular environment
tracks the extracellular concentration of ADMA when
the latter varies rapidly. Nor is it clear whether high
extracellular ADMA has biological effects in its own
right or is merely a marker of high intracellular levels
[3]. Alternatively, our results could mean that inhibition
of NOS by accumulated ADMA is not the main culprit
for reduced NO bioactivity in ESRD patients. Other
potential mechanisms include scavenging of NO by
ROS (reactive oxygen species), reduced expression of
eNOS [4], possibly mediated by the accumulation of
advanced glycation end-products [63], deficient supply
of l-arginine or inhibition of l-arginine transport into
cells [34].
Study limitations
One limitation of the present study is that the potential
vascular impact of HD was not tested in isovolaemic
conditions, as shown by the substantial ultrafiltration
volume withdrawn from patients (Table 2). The
resulting decrease in BP (Table 3) may have triggered
a baroreflex-mediated sympatho-adrenergic activation,
with the resulting vasoconstriction then masking any
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positive influence of reduced ADMA levels on thermal
hyperaemia. Although not supported by the absence
of any effect of HD on basal SkBF (Table 3), this
interpretation of our findings cannot be ruled out. In
practical terms, however, our results would still imply a
limited or non-existent overall impact of acutely reduced
ADMA levels on NO-dependent skin vasodilation, since
HD is not usually carried out in isovolaemic conditions.
The temperature of the dialysate was kept at 37 ◦C. In
such conditions, it is possible that HD caused an increase
in core temperature [64], thus adding a complicating
influence on the regulation of SkBF [65]. However, if
there were core temperature changes in our present study,
they appear to have had a minimal influence on the
cutaneous microcirculation, since skin temperature as
well as basal SkBF were unaffected by HD (Table 3).
Another possible limitation is the fact that microvas-
cular reactivity as well as blood parameters were not
determined before and after the sameHD session, for the
specific reasons indicated in the Materials and methods
section. However, this feature of our study design has
limited potential for confounding, because, in every
patient, HD prescription was identical between the two
successive HD sessions. In stable ESRD patients (as were
those of the present study), haemodynamic conditions
either before or after HD are reproducible between HD
sessions [66].
Finally, for the reasons explained in the Materials and
methods section, plasma levels of ADMA and l-arginine
were assayed with different methods. As long as each
analytewas consistently assayedwith the same technique,
however, the validity of comparisons made between the
groups as well as within the HD group (Figure 3) should
not be affected.
Conclusions
In summary, thepresent study shows for thefirst time that
endothelial NO-dependent vasodilation in the cutaneous
microcirculation is not influenced by the plasma
level of ADMA in patients on maintenance HD.
These results suggest that mechanisms other than or
in addition to inhibition of eNOS by accumulated
ADMA are responsible for endothelial dysfunction in
these patients. They call into question the concept
that the accumulation of ADMA is a causal factor for
the increased cardiovascular risk in ESRD patients and
suggest that ADMA is more likely to represent just a
marker of the highly atherogenic environment caused by
CKD.
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